Literature DB >> 18627326

Major bleeding: management and risk reduction in acute coronary syndromes.

Matthew A Cavender1, Sunil V Rao, E Magnus Ohman.   

Abstract

BACKGROUND: Guidelines for the management of high-risk non ST-segment elevation acute coronary syndrome (NSTE ACS) recommend antithrombotic and antiplatelet therapy combined with an early invasive strategy. While this strategy reduces ischemic complications, it places patients at risk for bleeding complications.
OBJECTIVE: We sought to provide a narrative review of the risk factors for bleeding, risks associated with bleeding and strategies to prevent bleeding complications.
METHODS: A comprehensive literature review was performed to identify relevant evidence. RESULTS/
CONCLUSIONS: Bleeding complications in NSTE ACS are associated with adverse events and higher mortality. Prevention of bleeding complications can be achieved through judicious dosing of medications, the use of antithrombotic agents associated with a lower bleeding risk and use of the radial artery approach in patients requiring coronary intervention. Future work should focus on delineating the mechanisms underlying the bleeding-mortality relationship and developing a better understanding of the tradeoff between efficacy and safety.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18627326     DOI: 10.1517/14656566.9.11.1869

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  3 in total

Review 1.  Bleeding associated with current therapies for acute coronary syndrome: what are the mechanisms?

Authors:  Matthew A Cavender; Sunil V Rao
Journal:  J Thromb Thrombolysis       Date:  2010-10       Impact factor: 2.300

2.  Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial.

Authors:  Matthew A Cavender; Benjamin M Scirica; Marc P Bonaca; Dominick J Angiolillo; Anthony J Dalby; Mikael Dellborg; Joao Morais; Sabina A Murphy; Ton Oude Ophuis; Michal Tendera; Eugene Braunwald; David A Morrow
Journal:  Circulation       Date:  2015-02-13       Impact factor: 29.690

3.  Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX.

Authors:  Matthew A Cavender; Robert A Harrington; Gregg W Stone; Ph Gabriel Steg; C Michael Gibson; Christian W Hamm; Matthew J Price; Renato D Lopes; Sergio Leonardi; Efthymios N Deliargyris; Jayne Prats; Kenneth W Mahaffey; Harvey D White; Deepak L Bhatt
Journal:  Circ Cardiovasc Interv       Date:  2021-12-17       Impact factor: 7.514

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.